CY2007016I2 - Εμβολιο ιου θηλωματος - Google Patents

Εμβολιο ιου θηλωματος

Info

Publication number: CY2007016I2
Authority: CY; Cyprus
Prior art keywords: hpv vaccine; hpv; vaccine
Prior art date: 1991-07-19

Application number

CY200700016C

Other languages

English (en)

Other versions

CY2007016I1 (el

Original Assignee

University Of Queensland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-19

Filing date

2007-08-06

Publication date

2009-11-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3775561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2007016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-06 Application filed by University Of Queensland filed Critical University Of Queensland

2009-11-04 Publication of CY2007016I2 publication Critical patent/CY2007016I2/el

2009-11-04 Publication of CY2007016I1 publication Critical patent/CY2007016I1/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20041—Use of virus, viral particle or viral elements as a vector
- C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Analytical Chemistry (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)

CY200700016C 1991-07-19 2007-08-06 Εμβολιο ιου θηλωματος CY2007016I1 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPK732291		1991-07-19
PCT/AU1992/000364 WO1993002184A1 (en)	1991-07-19	1992-07-20	Papilloma virus vaccine

Publications (2)

Publication Number	Publication Date
CY2007016I2 true CY2007016I2 (el)	2009-11-04
CY2007016I1 CY2007016I1 (el)	2009-11-04

Family

ID=3775561

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
CY0700013A CY2598B2 (en)	1991-07-19	2007-07-20	Papilloma virus vaccine
CY200700016C CY2007016I1 (el)	1991-07-19	2007-08-06	Εμβολιο ιου θηλωματος
CY2007015C CY2007015I2 (el)	1991-07-19	2007-08-06	Εμβολιο εναντια στον ανθρωπινο ιο θηλωματος
CY2007034C CY2007034I1 (el)	1991-07-19	2007-12-14	Εμβολιο εναντια στον ανθρωπινο ϊο θηλωματος (τυπος 18)
CY2007030C CY2007030I2 (el)	1991-07-19	2007-12-14	Εμβολιο εναντια στον ανθρωπινο ϊο θηλωματος (τυπος 18)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY0700013A CY2598B2 (en)	1991-07-19	2007-07-20	Papilloma virus vaccine

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
CY2007015C CY2007015I2 (el)	1991-07-19	2007-08-06	Εμβολιο εναντια στον ανθρωπινο ιο θηλωματος
CY2007034C CY2007034I1 (el)	1991-07-19	2007-12-14	Εμβολιο εναντια στον ανθρωπινο ϊο θηλωματος (τυπος 18)
CY2007030C CY2007030I2 (el)	1991-07-19	2007-12-14	Εμβολιο εναντια στον ανθρωπινο ϊο θηλωματος (τυπος 18)

Country Status (16)

Country	Link
US (5)	US7476389B1 (el)
EP (5)	EP1359156B1 (el)
JP (3)	JP3828570B2 (el)
KR (1)	KR100240480B1 (el)
AT (3)	ATE356142T1 (el)
AU (1)	AU651727B2 (el)
CA (1)	CA2113712C (el)
CY (5)	CY2598B2 (el)
DE (11)	DE122007000017I1 (el)
DK (3)	DK1359156T3 (el)
ES (3)	ES2267890T3 (el)
GE (1)	GEP20084431B (el)
LU (8)	LU91317I2 (el)
NL (8)	NL300262I1 (el)
SG (1)	SG48769A1 (el)
WO (1)	WO1993002184A1 (el)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1359156B1 (en)	1991-07-19	2007-03-07	University of Queensland	Vaccine against Human Papillomavirus (Type 18)
DE122007000098I1 (de) *	1992-06-25	2008-03-27		Papillomavirus vakzine
US5437951A (en) *	1992-09-03	1995-08-01	The United States Of America As Represented By The Department Of Health And Human Services	Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) *	1992-09-03	1997-04-08	The United States Of America As Represented By The Department Of Health And Human Services	Chimeric papillomavirus-like particles
US20020164350A1 (en)	1992-09-03	2002-11-07	Lowy Douglas R.	Chimeric papillomavirus-like particles
DE122011100018I1 (de) *	1993-03-09	2011-11-17	Univ Rochester	Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
US6153201A (en) *	1993-03-09	2000-11-28	University Of Rochester	Oral immunization with papillomavirus virus-like particles
US8062642B1 (en)	1993-03-09	2011-11-22	University Of Rochester	Production of papillomavirus capsid protein and virus-like particles
AU719837B2 (en) *	1993-03-31	2000-05-18	Cancer Research Campaign Technology Limited	Pharmaceuticals based on papillomaviruses
GB9306731D0 (en) *	1993-03-31	1993-05-26	Cancer Res Campaign Tech	Vaccines
GB2279651A (en) *	1993-07-01	1995-01-11	British Tech Group	Synthetic peptides of human papillomavirus
GB9313556D0 (en) *	1993-07-01	1993-08-18	British Tech Group	Synthetic peptides of human papillomavirus
AUPM358894A0 (en) *	1994-01-31	1994-02-24	Csl Limited	Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) *	1994-05-04	1996-10-10	Deutsches Krebsforsch	Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) *	1994-05-16	1999-03-30	Merck & Co. Inc.	Recombinant papillomavirus vaccines
CZ336696A3 (en) *	1994-05-16	1997-07-16	Merck & Co Inc	Isolated and purified proteins of papillomavirus and process for preparing thereof
AUPM566794A0 (en) *	1994-05-17	1994-06-09	University Of Queensland, The	Process and product
IL113817A (en) *	1994-06-30	2001-03-19	Merck & Co Inc	Polynucleotide vaccne for papillomavirus
AU717932B2 (en) *	1994-10-06	2000-04-06	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Chimeric papillomavirus-like particles
AU717647B2 (en) *	1994-10-06	2000-03-30	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Chimeric papillomavirus-like particles
DE122007000093I1 (de) *	1994-10-07	2008-03-27	Univ Loyola Chicago	Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
DE4447664C2 (de) *	1994-10-07	1999-04-15	Lutz Prof Dr Gissmann	Fusionsproteine, Verfahren zu deren Herstellung sowie deren Anwendung
AU2003235191B2 (en) *	1994-10-07	2006-09-21	Loyola University Of Chicago	Papilloma virus-like particles, fusion proteins as well as processes for their production
DE19526752C2 (de) *	1995-07-21	1997-08-07	Lutz Prof Dr Gissmann	Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
AR004464A1 (es) *	1994-11-14	1998-12-16	Merck Sharp & Dohme	Un metodo para producir una proteina de capside de papilomavirus
AU4727296A (en) *	1995-02-24	1996-09-11	Cantab Pharmaceuticals Research Limited	Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
GB9505784D0 (en) *	1995-03-22	1995-05-10	Lynxvale Ltd	Anti-tumour treatment
IL117459A (en) *	1995-03-22	2005-11-20	Merck & Co Inc	Dna encoding human papillomavirus type 18
US5820870A (en) *	1995-03-22	1998-10-13	Merck & Co., Inc.	Recombinant human papillomavirus type 18 vaccine
US5840306A (en) *	1995-03-22	1998-11-24	Merck & Co., Inc.	DNA encoding human papillomavirus type 18
US5821087A (en) *	1995-03-30	1998-10-13	Merck & Co., Inc.	Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) *	1995-03-30	1996-07-23	Merck & Co Inc	Synthetic DNA encoding human papillomavirus type 11 L1 protein
SE9501512D0 (sv) *	1995-04-24	1995-04-24	Euro Diagnostica Ab	Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
JP2000501285A (ja) *	1995-11-15	2000-02-08	メルクエンドカンパニーインコーポレーテッド	合成ｈｐｖ１１ウイルス様粒子
US6908615B1 (en)	1996-03-18	2005-06-21	Merck & Co., Inc.	DNA encoding human papilloma virus type 18
FR2749323B1 (fr) *	1996-06-04	1998-07-10	Pasteur Merieux Serums Vacc	Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
US7118754B1 (en)	1996-07-30	2006-10-10	Transgene S.A.	Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) *	1996-07-30	1998-10-30	Transgene Sa	Composition pharmaceutique contre les tumeurs et infections a papillomavirus
CA2267639C (en) *	1996-10-04	2005-11-22	Merck & Co., Inc.	Synthetic hpv16 virus-like particles
GB9621091D0 (en)	1996-10-09	1996-11-27	Fondation Pour Le Perfectionem	Attenuated microorganisms strains and their uses
ES2213841T3 (es) *	1996-12-09	2004-09-01	MERCK & CO., INC.	Particulas sinteticas semejantes al virus hpv16.
ES2273376T3 (es) *	1996-12-20	2007-05-01	MERCK & CO., INC.	Formulaciones de vacunas recombinantes frente a papilomas.
EP0980257A1 (en) *	1997-05-01	2000-02-23	Chiron Corporation	Use of virus-like particles as adjuvants
EP1000157A1 (en) *	1997-07-03	2000-05-17	University Technology Corporation	Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
FR2766091A1 (fr)	1997-07-18	1999-01-22	Transgene Sa	Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6962777B1 (en) *	1997-09-05	2005-11-08	Medimmune, Inc.	In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en)	1997-10-06	2001-05-08	Loyola University Of Chicago	Papilloma virus capsomere formulations and method of use
US7494658B2 (en)	1998-02-20	2009-02-24	Medigene Ag	Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (en)	1998-02-20	2003-12-09	Medigene Gmbh	Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en)	1998-02-20	2007-02-27	Medigene Ag	Papillomavirus truncated L1 protein and fusion protein constructs
US20020039584A1 (en)	1998-02-20	2002-04-04	Medigene Ag	Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en)	1998-03-24	2005-08-09	Medigene Aktiengesellschaft	Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en)	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
AUPP765398A0 (en)	1998-12-11	1999-01-14	University Of Queensland, The	Treatment of papillomavirus infections
DE19925199A1 (de) *	1999-06-01	2000-12-07	Medigene Ag	Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925234A1 (de) *	1999-06-01	2000-12-14	Medigene Ag	Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) *	1999-06-01	2000-12-07	Medigene Ag	Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
GB9921146D0 (en) *	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
GB0109297D0 (en)	2001-04-12	2001-05-30	Glaxosmithkline Biolog Sa	Vaccine
AUPR446801A0 (en)	2001-04-18	2001-05-17	University Of Queensland, The	Novel compositions and uses therefor
KR100785397B1 (ko)	2001-06-28	2007-12-13	아피메즈 주식회사	인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
DE10137102A1 (de)	2001-07-30	2003-02-27	Deutsches Krebsforsch	Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
WO2003103570A2 (en)	2001-08-01	2003-12-18	University Of Rochester	Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
US20050118139A1 (en) *	2001-08-23	2005-06-02	Lingyi Huang	Vaccine using papilloma virus e proteins delivered by viral vector
KR20030067873A (ko) *	2002-02-08	2003-08-19	주식회사 유니크	솔레노이드 밸브
GB0206360D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
CA2678736A1 (en)	2003-07-21	2005-02-17	Transgene S.A.	Novel multifunctional il-2 - il-18 fusion proteins
WO2005030041A2 (en)	2003-09-25	2005-04-07	Third Wave Technologies, Inc.	Detection of hpv
CA2579882C (en) *	2004-09-10	2012-07-17	Asahi Glass Company, Limited	Edible vaccine
US8021992B2 (en) *	2005-09-01	2011-09-20	Taiwan Semiconductor Manufacturing Co., Ltd.	High aspect ratio gap fill application using high density plasma chemical vapor deposition
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
US8080643B2 (en) *	2006-09-05	2011-12-20	Third Wave Technologies, Inc.	HPV primers
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
DK2468300T3 (da)	2006-09-26	2018-01-29	Infectious Disease Res Inst	Vaccinesammensætning indeholdende syntetisk adjuvant
US20090098529A1 (en)	2006-10-16	2009-04-16	Nanhai Chen	Methods for attenuating virus strains for diagnostic and therapeutic uses
CL2008000611A1 (es)	2007-03-02	2008-09-05	Glaxosmithkline Biolog Sa	Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
KR101588413B1 (ko) *	2007-11-23	2016-02-02	상하이 제런 바이오테크놀러지 코포레이션 리미티드	인간 파필로마 바이러스의 주요 캡시드 단백질 ｌ1을 암호화하는 유전자 및 이의 용도
WO2009088256A2 (ko) *	2008-01-09	2009-07-16	Konkuk University Industrial Cooperation Corp	배큘로바이러스-기반 백신
CN106377767A (zh)	2008-05-26	2017-02-08	卡迪拉保健有限公司	麻疹‑人乳头瘤组合疫苗
GB0815872D0 (en)	2008-09-01	2008-10-08	Pasteur Institut	Novel method and compositions
GB0820822D0 (en)	2008-11-13	2008-12-24	Inst Catala D Oncologia	Novel product and processes
US20120115207A1 (en) *	2009-04-03	2012-05-10	Deutsches Krebsforschungszentrum	Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
JP5830015B2 (ja)	2009-06-05	2015-12-09	インフェクシャスディズィーズリサーチインスティチュート	合成グルコピラノシル脂質アジュバント
BRPI0924981B1 (pt)	2009-06-19	2022-02-08	Eyegene Inc	Composição de vacina para câncer cervical
WO2011026111A1 (en)	2009-08-31	2011-03-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Oral delivery of a vaccine to the large intestine to induce mucosal immunity
EP2556377B1 (en)	2010-04-08	2017-07-12	University of Pittsburgh - Of the Commonwealth System of Higher Education	B-cell antigen presenting cell assay
EP2576840B1 (en)	2010-05-25	2018-10-17	QIAGEN Gaithersburg, Inc.	Fast results hybrid capture assay and associated strategically-truncated probes
KR101349291B1 (ko)	2010-08-10	2014-01-10	한국생명공학연구원	고초균을 이용하여 자궁경부암 백신을 제조하는 방법
EA027236B1 (ru)	2011-04-08	2017-07-31	Иммьюн Дизайн Корп.	Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
RS58868B1 (sr)	2012-02-07	2019-08-30	Infectious Disease Res Inst	Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
BR112014023092A8 (pt)	2012-03-18	2017-07-25	Glaxosmithkline Biologicals Sa	Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
EP3388835B1 (en)	2012-05-16	2020-04-01	Immune Design Corp.	Vaccines for hsv-2
JP6430949B2 (ja)	2012-10-23	2018-11-28	エモリーユニバーシティ	Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
KR102039520B1 (ko)	2013-04-18	2019-11-01	이뮨 디자인 코포레이션	암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
US11801223B2 (en)	2013-12-31	2023-10-31	Access To Advanced Health Institute	Single vial vaccine formulations
WO2016149384A1 (en) *	2015-03-18	2016-09-22	University Of Massachusetts	Virus-like particle compositions and vaccines against epstein-barr virus infection and disease
KR101908438B1 (ko) *	2016-02-05	2018-10-16	(주)피앤피바이오팜	Arsntd를 융합파트너로 이용한 수용성 및 활성형 재조합단백질의 생산방법 및 그 생산물
JP7005504B2 (ja)	2016-02-22	2022-01-21	ベーリンガーインゲルハイムフェトメディカゲーエムベーハー	生体分子の固定化方法
JP7195147B2 (ja)	2016-05-16	2022-12-23	アクセスツーアドバンストヘルスインスティチュート	Ｐｅｇ化リポソームおよび使用方法
IL314130A (en)	2016-05-16	2024-09-01	Access To Advanced Health Inst	Formulation containing tlr agonist and methods of use
US11173126B2 (en)	2016-06-01	2021-11-16	Infectious Disease Research Institute	Nanoalum particles comprising a PAA sizing agent
CN111315362A (zh)	2017-06-15	2020-06-19	传染病研究所	纳米结构脂质载剂和稳定乳剂以及其用途
CN111315406A (zh)	2017-09-08	2020-06-19	传染病研究所	包括皂苷的脂质体调配物及其使用方法
RU2681174C1 (ru) *	2018-07-12	2019-03-04	Закрытое акционерное общество научно-производственная компания "Комбиотех"	Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
CN114340665A (zh)	2019-05-25	2022-04-12	传染病研究所	用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
JP7017811B2 (ja) *	2020-02-13	2022-02-09	国立研究開発法人農業・食品産業技術総合研究機構	ウイルス様粒子及びその使用
AU2021337493A1 (en)	2020-09-04	2023-05-18	Access To Advanced Health Institute	Co-lyophilized rna and nanostructured lipid carrier
US20240131140A1 (en)	2021-02-11	2024-04-25	Glaxosmithkline Biologicals Sa	Hpv vaccine manufacture
CN118451477A (zh) *	2021-12-29	2024-08-06	株式会社日立高新技术	微生物图像解析方法
AU2023336224A1 (en)	2022-09-09	2025-03-27	Access To Advanced Health Institute	Immunogenic vaccine composition incorporating a saponin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2524487B1 (fr)	1982-04-05	1985-11-22	Pasteur Institut	Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US5071757A (en)	1986-10-06	1991-12-10	Kreider John W	Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US5045447A (en)	1989-03-15	1991-09-03	Minson Anthony C	Method of producing antibodies to HPV
NL8902301A (nl) *	1989-09-14	1991-04-02	Rijksuniversiteit	Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins.
WO1992016638A1 (en)	1991-03-14	1992-10-01	5 Prime --> 3 Prime, Inc.	Transduction vehicles for transferring dna to a mammalian cell
EP1359156B1 (en) *	1991-07-19	2007-03-07	University of Queensland	Vaccine against Human Papillomavirus (Type 18)
DE122007000098I1 (de)	1992-06-25	2008-03-27		Papillomavirus vakzine
US5437951A (en)	1992-09-03	1995-08-01	The United States Of America As Represented By The Department Of Health And Human Services	Self-assembling recombinant papillomavirus capsid proteins
DE122011100018I1 (de)	1993-03-09	2011-11-17	Univ Rochester	Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.

1992
- 1992-07-20 EP EP03005929A patent/EP1359156B1/en not_active Expired - Lifetime
- 1992-07-20 KR KR1019940700169A patent/KR100240480B1/ko not_active Expired - Lifetime
- 1992-07-20 DE DE200712000017 patent/DE122007000017I1/de active Pending
- 1992-07-20 AT AT03005929T patent/ATE356142T1/de active
- 1992-07-20 DE DE122007000084C patent/DE122007000084I1/de active Pending
- 1992-07-20 ES ES02009841T patent/ES2267890T3/es not_active Expired - Lifetime
- 1992-07-20 DE DE69233639T patent/DE69233639T2/de not_active Expired - Lifetime
- 1992-07-20 DE DE122007000085C patent/DE122007000085I1/de active Pending
- 1992-07-20 DE DE122007000086C patent/DE122007000086I1/de active Pending
- 1992-07-20 DK DK03005929T patent/DK1359156T3/da active
- 1992-07-20 US US08/185,928 patent/US7476389B1/en active Active
- 1992-07-20 DE DE200712000019 patent/DE122007000019I1/de active Pending
- 1992-07-20 EP EP01126938A patent/EP1207203A3/en not_active Withdrawn
- 1992-07-20 AU AU23666/92A patent/AU651727B2/en not_active Expired
- 1992-07-20 DE DE69233687T patent/DE69233687T2/de not_active Expired - Lifetime
- 1992-07-20 SG SG1996001490A patent/SG48769A1/en unknown
- 1992-07-20 DE DE69232967T patent/DE69232967T2/de not_active Expired - Lifetime
- 1992-07-20 DK DK92915973T patent/DK0595935T3/da active
- 1992-07-20 EP EP04014651A patent/EP1471147A3/en not_active Withdrawn
- 1992-07-20 EP EP02009841A patent/EP1298211B1/en not_active Expired - Lifetime
- 1992-07-20 ES ES92915973T patent/ES2194839T3/es not_active Expired - Lifetime
- 1992-07-20 ES ES03005929T patent/ES2279020T3/es not_active Expired - Lifetime
- 1992-07-20 DE DE1992633639 patent/DE122007000018I1/de active Pending
- 1992-07-20 CA CA002113712A patent/CA2113712C/en not_active Expired - Lifetime
- 1992-07-20 AT AT92915973T patent/ATE234925T1/de active
- 1992-07-20 WO PCT/AU1992/000364 patent/WO1993002184A1/en active IP Right Grant
- 1992-07-20 AT AT02009841T patent/ATE332973T1/de active
- 1992-07-20 EP EP92915973A patent/EP0595935B1/en not_active Expired - Lifetime
- 1992-07-20 DE DE200712000023 patent/DE122007000023I1/de active Pending
- 1992-07-20 DK DK02009841T patent/DK1298211T3/da active
- 1992-07-20 DE DE1992632967 patent/DE122007000016I1/de active Pending
- 1992-07-20 JP JP50248693A patent/JP3828570B2/ja not_active Expired - Lifetime
2001
- 2001-09-07 US US09/947,372 patent/US6613557B1/en not_active Expired - Fee Related
2003
- 2003-08-18 JP JP2003294384A patent/JP2004000269A/ja not_active Withdrawn
- 2003-12-11 US US10/732,345 patent/US7169585B2/en not_active Expired - Fee Related
2005
- 2005-11-24 JP JP2005339177A patent/JP4255944B2/ja not_active Expired - Lifetime
2006
- 2006-06-19 US US11/455,236 patent/US20070154902A1/en not_active Abandoned
2007
- 2007-02-21 NL NL300262C patent/NL300262I1/nl unknown
- 2007-02-21 NL NL300263C patent/NL300263I1/nl unknown
- 2007-02-21 NL NL300260C patent/NL300260I1/nl unknown
- 2007-02-21 NL NL300261C patent/NL300261I1/nl unknown
- 2007-02-27 LU LU91317C patent/LU91317I2/fr unknown
- 2007-02-27 LU LU91318C patent/LU91318I2/fr unknown
- 2007-02-27 LU LU91316C patent/LU91316I2/fr unknown
- 2007-02-27 LU LU91315C patent/LU91315I2/fr unknown
- 2007-03-07 NL NL300266C patent/NL300266I1/nl unknown
- 2007-03-09 LU LU91321C patent/LU91321I2/fr unknown
- 2007-07-20 GE GEAP200710179A patent/GEP20084431B/en unknown
- 2007-07-20 CY CY0700013A patent/CY2598B2/xx unknown
- 2007-08-06 CY CY200700016C patent/CY2007016I1/el unknown
- 2007-08-06 CY CY2007015C patent/CY2007015I2/el unknown
- 2007-12-14 CY CY2007034C patent/CY2007034I1/el unknown
- 2007-12-14 CY CY2007030C patent/CY2007030I2/el unknown
- 2007-12-14 LU LU91385C patent/LU91385I2/fr unknown
- 2007-12-14 NL NL300314C patent/NL300314I2/nl unknown
- 2007-12-14 NL NL300313C patent/NL300313I1/nl unknown
- 2007-12-14 LU LU91386C patent/LU91386I2/fr unknown
- 2007-12-14 NL NL300312C patent/NL300312I1/nl unknown
- 2007-12-14 LU LU91387C patent/LU91387I2/fr unknown
2008
- 2008-12-22 US US12/318,138 patent/US7939082B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1359156A3 (en)	2004-03-24
LU91318I2 (fr)	2007-04-27
CY2007016I1 (el)	2009-11-04
NL300261I1 (nl)	2007-05-01
WO1993002184A1 (en)	1993-02-04
EP1471147A3 (en)	2007-03-21
DE122007000085I1 (de)	2008-03-27
EP1298211A2 (en)	2003-04-02
CA2113712A1 (en)	1993-02-04
CY2598B2 (en)	2010-03-03
LU91385I2 (fr)	2008-02-14
CY2007034I1 (el)	2012-01-25
JP3828570B2 (ja)	2006-10-04
SG48769A1 (en)	1998-05-18
HK1059271A1 (en)	2004-06-25
LU91386I2 (fr)	2008-02-14
NL300314I1 (nl)	2008-02-01
DE122007000019I1 (de)	2007-07-26
DE122007000017I1 (de)	2007-07-26
DE122007000023I1 (de)	2007-08-09
LU91317I2 (fr)	2007-04-27
EP1298211B1 (en)	2006-07-12
ATE234925T1 (de)	2003-04-15
CY2007015I2 (el)	2016-08-31
ES2194839T3 (es)	2003-12-01
NL300312I1 (nl)	2008-02-01
CY2007015I1 (el)	2009-11-04
EP0595935A1 (en)	1994-05-11
US6613557B1 (en)	2003-09-02
EP0595935A4 (en)	1995-03-29
US7476389B1 (en)	2009-01-13
LU91316I2 (fr)	2007-04-27
EP1207203A2 (en)	2002-05-22
US7169585B2 (en)	2007-01-30
JPH07505042A (ja)	1995-06-08
CY2007030I1 (el)	2012-01-25
DK0595935T3 (da)	2003-07-21
LU91387I2 (fr)	2008-02-14
EP0595935B1 (en)	2003-03-19
AU2366692A (en)	1993-02-23
GEP20084431B (en)	2008-07-25
EP1207203A3 (en)	2004-04-28
ATE332973T1 (de)	2006-08-15
CY2007030I2 (el)	2017-04-05
DE69232967T2 (de)	2003-12-18
DE122007000086I1 (de)	2008-04-17
US20090252761A1 (en)	2009-10-08
ES2279020T3 (es)	2007-08-16
KR100240480B1 (ko)	2000-03-02
NL300263I1 (nl)	2007-05-01
DE69233639D1 (de)	2006-08-24
NL300266I1 (nl)	2007-05-01
EP1359156A2 (en)	2003-11-05
DK1359156T3 (da)	2007-04-10
NL300313I1 (nl)	2008-02-01
DE122007000016I1 (de)	2007-05-24
US7939082B2 (en)	2011-05-10
ATE356142T1 (de)	2007-03-15
NL300262I1 (nl)	2007-05-01
JP4255944B2 (ja)	2009-04-22
NL300260I1 (nl)	2007-05-01
JP2006115849A (ja)	2006-05-11
CA2113712C (en)	2007-06-12
EP1359156B1 (en)	2007-03-07
DE69233687T2 (de)	2007-10-18
NL300314I2 (nl)	2010-03-01
LU91321I2 (fr)	2007-05-09
JP2004000269A (ja)	2004-01-08
EP1298211A3 (en)	2003-04-16
DE122007000018I1 (de)	2007-05-24
DE69233639T2 (de)	2007-05-31
US20040214331A1 (en)	2004-10-28
DE69232967D1 (de)	2003-04-24
EP1471147A2 (en)	2004-10-27
DE122007000084I1 (de)	2008-03-27
AU651727B2 (en)	1994-07-28
ES2267890T3 (es)	2007-03-16
DK1298211T3 (da)	2006-11-13
DE69233687D1 (de)	2007-04-19
LU91315I2 (fr)	2007-04-27
US20070154902A1 (en)	2007-07-05

Publication	Publication Date	Title
CY2007016I2 (el)	2009-11-04	Εμβολιο ιου θηλωματος
DE69126606D1 (de)	1997-07-24	Vakzine
NO930699D0 (no)	1993-02-26	Hoeyeffektiv vaeske/vaeske hydrosyklon
DK0671948T3 (da)	1997-09-01	Vaccinepræparat indeholdende adjuvanser
FI943171L (fi)	1994-09-01	Ureaasipohjainen rokote Helicobacter-infektiota vastaan
FI964592L (fi)	1996-11-15	Papilloomavirusrokotteita
FI931169A7 (fi)	1993-04-22	Parannetut rokotekoostumukset
DK272889D0 (da)	1989-06-02	Vaccine
ATE137279T1 (de)	1996-05-15	Stoffauflauf
FI924456L (fi)	1993-04-05	Laekemedel
FI944052L (fi)	1994-09-02	Oraalinen rokote
FI935315A0 (fi)	1993-11-29	En flat packningscontainer
ATA131391A (de)	1992-09-15	Reibring
FI924701A7 (fi)	1993-04-19	Sakeutusaine
FI925032L (fi)	1992-11-06	Vaccinsammansaettningar
FI942347L (fi)	1994-07-04	Putki
FI906051A7 (fi)	1991-06-09	Malariarokote
ATA39792A (de)	1994-11-15	Maehwerk
ATA170491A (de)	1993-02-15	Mauerstein
DK56591D0 (da)	1991-03-27	Toerringsfremgangsmaade
DK0718273T3 (da)	1998-04-06	Ethyl-6-formyloxy-4-hexenoat
NO933600D0 (no)	1993-10-08	Termostabile virus
ATA67791A (de)	1992-05-15	Rollski
FI902206A7 (fi)	1990-11-04	Malariarokote
FI925278A7 (fi)	1992-11-20	Kattila